9 results
Primary: To demonstrate the non-inferior antiviral activity of switching to DTG + RPV once daily compared to continuation of current antiretroviral regimen (CAR) over 48 weeks in HIV-1 infected antiretroviral therapy (ART) experienced subjects.…
Primary Objective:To evaluate the long-term safety and tolerability of eptinezumab in patients with chronic cluster headache (cCH)Secondary ObjectivesTo evaluate the efficacy of eptinezumab in patients with cCHExploratory ObjectiveTo explore the…
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…
Primary Objective• To evaluate the efficacy of eptinezumab as add-on to BI for the prevention of migraine and treatment of MOHSecondary Objectives• To evaluate the efficacy of eptinezumab as add-on to BI on health-related quality of life and work…
The primary objective is to influence amygdala and ventral striatum neuronal activity, thereby changing their influence on consequent approach/avoidance decisions, as indicated with left or right button presses.
Primary:To demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks compared to remaining on ABC/DTG/3TC (or DTG and an approved dual-NRTI scheme) over 48 weeks.Secondary:To…
Primary Objective:- To evaluate the efficacy of eptinezumab in patients with eCHSecondary Objectives:- To evaluate the efficacy of eptinezumab on health-related quality of life, health care resource utilization, and work productivitySafety…
To characterize the single-dose pharmacokinetic (PK) of RPV after SC administration of RPV LA suspensions with different doses and/or different particle size (PS) to support further dose and formulation selection, in healthy adult participants.To…
The overall objective of the CAB LA + RPV LA clinical development programme is to develop a highly effective, well-tolerated, two-drug, long-acting injectable regimen which has the potential to offer improved treatment convenience, compliance and…